In a report released today, Constantine Davides from JMP Securities maintained a Hold rating on Certara (CERT – Research Report). The company’s shares closed yesterday at $17.66.
According to TipRanks, Davides is an analyst with an average return of -29.6% and a 20.83% success rate. Davides covers the Healthcare sector, focusing on stocks such as AMN Healthcare Services, Cross Country Healthcare, and HealthStream.
The word on The Street in general, suggests a Hold analyst consensus rating for Certara with a $19.10 average price target.
CERT market cap is currently $2.82B and has a P/E ratio of -50.72.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Certara (CERT) Company Description:
Certara Inc accelerate medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides proven modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trial, accelerate regulatory approval and increase patient access to medicines.
Read More on CERT:
